Phosphodiesterase 1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphodiesterase 1 as ChEMBL target CHEMBL2111322, mapped to UniProt Q63421. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Phosphodiesterase 1 matters
Phosphodiesterase 1 is reviewed as Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C (UniProt Q63421); the current evidence base includes 2 approved drugs, 102 compounds, and 15 assays, with lead potency reaching pChEMBL 7.0.
Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Sequence length is 768 aa.
Review this target as Phosphodiesterase 1, mapped to UniProt Q63421. ChEMBL maps the protein component as Dual specificity calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C. Sequence length is 768 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 2 approved drugs, 102 compounds, and 15 assays for this target. The dominant activity type is IC50. CHEMBL275084 is the current potency anchor at pChEMBL 7.0.
Use CHEMBL275084 as the tractability anchor when discussing potency (pChEMBL 7.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Phosphodiesterase 1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q63421, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL275084
|
7.0 | IC50 | — |
|
|
No preferred name
CHEMBL310041
|
7.0 | IC50 | — |
|
|
No preferred name
CHEMBL444046
|
7.0 | IC50 | — |
|
|
No preferred name
CHEMBL192
|
6.6 | IC50 | Approved |
|
|
No preferred name
CHEMBL910
|
6.4 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
SILDENAFIL
CHEMBL192
|
1998 |